Results 261 to 270 of about 759,881 (390)
Influence of intravenous anesthetics on neuromonitoring of the recurrent laryngeal nerve during thyroid surgery. [PDF]
Chang PY+6 more
europepmc +1 more source
Magnetic Multifunctional Nanoparticles for Effective Targeted Cancer Therapy
To overcome physiological barriers and achieve prolonged tumor retention, core–shell nanoparticles (Fe3O4@SiO2@Au, termed FSA‐NPs) with gold‐decorated surfaces are constructed. FSA‐NPs exhibit strong magnetic resonance imaging (MRI) contrast and potent anticancer effects through the synergistic action of chemotherapy, magnetic targeting, and ...
Yao Miao+4 more
wiley +1 more source
Successful Local Anesthetic Systemic Toxicity (LAST) Management With Intralipid: A Case Emphasizing Post-stabilization Monitoring and 2020 American Society of Regional Anesthesia and Pain Medicine (ASRA) Updates. [PDF]
Farsani A, Nuveen NK.
europepmc +1 more source
A new ethoxyethanol derivative of iminofullerene, F2, is synthesized and labeled with 99mTc to produce 99mTc‐F2. In vitro, compound F2 inhibits the activation of primary mouse bone marrow‐derived macrophages stimulated with lipopolysaccharide. Moreover, 99mTc‐F2 is selectively enriched in the injured joints of mice. Inflammatory macrophages play a role
Rui He+6 more
wiley +1 more source
A pilot study on LC-MS/MS quantification of remifentanil, etomidate, and rocuronium in maternal and fetal serum microsamples. [PDF]
Liu H, Cai M, Peng Y, Miao JK, Yu J.
europepmc +1 more source
Objective The objective was to report the safety and efficacy of an anti‐IFNAR1 antibody (anifrolumab) in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who presented with vasculitic ulcers and systemic inflammation refractory to JAK inhibition (JAKi) and to the interferon‐β–neutralizing monoclonal antibody dazukibart ...
Sara Alehashemi+13 more
wiley +1 more source
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim+5 more
wiley +1 more source